SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending amid significant price volatility, with community chatter focused on identifying the bottom and anticipating the next launch catalyst. Concerns around potential delays and market manipulation are contrasted by bullish arguments highlighting institutional ownership and long-term potential in the space-based mobile network sector. Investors are closely watching for company announcements and launch dates to drive future price movement.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending downwards as community members discuss concerns around potential market manipulation and an AI bubble, especially following earnings. Traders are debating whether to buy the dip or prepare for a larger correction, while monitoring key support levels. Some are pointing to macro factors like interest rate expectations and geopolitical concerns as potential catalysts for further volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as the community debates whether its recent surge is overextended, despite a UBS price target boost. The stock's movements are tied to the broader AI narrative, particularly rising memory prices and potential supply constraints driven by demand for AI data centers. Traders are closely watching for management comments at an upcoming conference and Nvidia's earnings report for further catalysts.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heavy volatility, triggering discussions around margin calls and potential bear market conditions. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, influenced by factors like crypto sell-offs and uncertainty surrounding Federal Reserve policy. Concerns about overvaluation and the impact of potential rate cuts are also driving market anxieties.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around potential acquisition bids, particularly with a deadline approaching, fueling community discussion about possible outcomes and deal prices. Massive blocks of purchases are being noted, with chatter focusing on potential market manipulation and the involvement of key players like Comcast and Paramount Skydance.  News of HBO renewing a Game of Thrones series has also sparked some positive sentiment.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending amid discussions about the potential impact of SNAP benefit suspensions due to the government shutdown, with community members debating whether this will significantly hurt the retailer. Recent earnings and future guidance are also hot topics, alongside Walmart's strengths as a consumer staple during uncertain economic times. Additionally, the stock's technical patterns, like head and shoulders formations, are being analyzed for potential trading strategies.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's post-earnings stock movement is driving intense discussion, with the community debating whether concerns of an AI bubble are justified despite strong earnings and guidance. Some believe the sell-off is tied to broader market weakness and crypto liquidations, while others point to potential accounting issues or an impending recession. Despite varied opinions, analysts generally remain bullish, with many reiterating "Outperform" ratings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing volatile trading as investors debate the sustainability of the AI-driven semiconductor rally. Community members are closely watching for a potential market correction, with some anticipating a significant drop while others remain bullish on the sector's long-term prospects. NVIDIA's upcoming earnings and overall market sentiment are expected to be key drivers for SOXL's near-term performance.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing ($BA) is trending as the community discusses the stock's recent struggles despite positive developments like settling a strike and potential FAA approval for the 777X. Concerns persist around production stability, profitability, and the overall health of the company compared to its peers in the aerospace sector. Some traders speculate about share dilution and potential manipulation as driving forces behind the stock's downward trajectory.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about potential double tops and the possibility of further declines, with some speculating about drops to significantly lower levels. Community sentiment is mixed, ranging from concern over losses to opportunistic buying strategies, while others reference past market cycles and potential future black swan events. Broader discussions include quantum computing threats, the influence of large holders, and the impact of macroeconomic factors.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know

Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

Equity

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules Moleculin Announces Pricing of $3.5 Million Registered...

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds PR Newswire HOUSTON, Feb. 13, 2025 HOUSTON, Feb. 13...

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) Moleculin Receives Positive FDA Guidance for Acceleration of...

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial Moleculin Receives First Country Approval in Europe to...

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Participates in Virtual Investor 'What This Means' Segment Moleculin Participates in Virtual Investor 'What This Means' Segment PR Newswire HOUSTON, Jan. 27, 2025 Walter Klemp, CEO of...

This account has been verified as an official MBRX representative.

Verified Account

Moleculin Biotech

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Current Price	$0.434
Prev Close	$0.4382
Open	$0.4437
Dividend Yield	0.00%
50-Day Moving Average	$0.4634
Beta	0.89
Avg. Volume	4.02M
PE Ratio	-0.18

52-Week High	$3.65
52-Week Low	$0.25
Market Capitalization	$22.31M
EPS (Annual)	-$6.32
Price to Book	-0.81
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBRX News

MBRXMoleculin Biotech Inc